Email this article 
ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
- Authors: Volkova M.I.1
-
Affiliations:
- Departament of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 5, No 1 (2009)
- Pages: 64-67
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS
- Published: 30.03.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/208
- DOI: https://doi.org/10.17650/1726-9776-2009-5-1-64-67
- ID: 208
Cite item
Full Text
Abstract
Lucrin depot used to treat patients with prostate cancer has been investigated. The agent has been found to be highly effective, to causeadverse effects rarely, and to be well tolerated. The administration of leuproreline acetate yields the results comparable with those in the useof other luteining hormone-releasing hormone agonists and antagonists, bilateral orchiectomy, and estrogens.
About the authors
M. I. Volkova
Departament of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Russian Federation
References
Supplementary files
